2023 Q4 Form 10-Q Financial Statement
#000095017023062915 Filed on November 13, 2023
Income Statement
| Concept | 2023 Q4 | 2023 Q3 |
|---|---|---|
| Revenue | $0.00 | $0.00 |
| YoY Change | ||
| Cost Of Revenue | ||
| YoY Change | ||
| Gross Profit | ||
| YoY Change | ||
| Gross Profit Margin | ||
| Selling, General & Admin | $908.0K | $1.100M |
| YoY Change | -36.94% | -25.42% |
| % of Gross Profit | ||
| Research & Development | $111.0K | $1.859M |
| YoY Change | -94.61% | -41.37% |
| % of Gross Profit | ||
| Depreciation & Amortization | $10.00K | $15.00K |
| YoY Change | -33.33% | 0.0% |
| % of Gross Profit | ||
| Operating Expenses | $1.019M | $2.962M |
| YoY Change | -70.88% | -36.25% |
| Operating Profit | ||
| YoY Change | ||
| Interest Expense | -$4.000K | $0.00 |
| YoY Change | -108.89% | -100.0% |
| % of Operating Profit | ||
| Other Income/Expense, Net | -$4.000K | $0.00 |
| YoY Change | -108.89% | -100.0% |
| Pretax Income | -$1.023M | -$2.960M |
| YoY Change | -70.38% | -35.6% |
| Income Tax | ||
| % Of Pretax Income | ||
| Net Earnings | -$1.023M | -$2.962M |
| YoY Change | -70.38% | -35.55% |
| Net Earnings / Revenue | ||
| Basic Earnings Per Share | -$0.24 | -$1.83 |
| Diluted Earnings Per Share | -$0.24 | -$1.83 |
| COMMON SHARES | ||
| Basic Shares Outstanding | 3.388B | 1.746M |
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2023 Q4 | 2023 Q3 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $658.0K | $220.0K |
| YoY Change | -86.5% | -96.89% |
| Cash & Equivalents | $658.0K | $216.0K |
| Short-Term Investments | ||
| Other Short-Term Assets | $425.0K | $570.0K |
| YoY Change | -90.13% | -46.78% |
| Inventory | ||
| Prepaid Expenses | $311.0K | $567.0K |
| Receivables | ||
| Other Receivables | ||
| Total Short-Term Assets | $1.186M | $783.0K |
| YoY Change | -87.08% | -90.4% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $699.0K | $694.0K |
| YoY Change | -5.41% | -7.96% |
| Goodwill | ||
| YoY Change | ||
| Intangibles | ||
| YoY Change | ||
| Long-Term Investments | ||
| YoY Change | ||
| Other Assets | ||
| YoY Change | ||
| Total Long-Term Assets | $699.0K | $694.0K |
| YoY Change | -5.41% | -86.27% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $1.186M | $783.0K |
| Total Long-Term Assets | $699.0K | $694.0K |
| Total Assets | $1.885M | $1.477M |
| YoY Change | -80.99% | -88.82% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $1.722M | $3.000M |
| YoY Change | -36.01% | 1.94% |
| Accrued Expenses | ||
| YoY Change | ||
| Deferred Revenue | ||
| YoY Change | ||
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | ||
| YoY Change | ||
| Total Short-Term Liabilities | $1.870M | $3.336M |
| YoY Change | -42.27% | -5.12% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Other Long-Term Liabilities | $179.0K | $170.0K |
| YoY Change | 123.75% | 123.68% |
| Total Long-Term Liabilities | $179.0K | $170.0K |
| YoY Change | 123.75% | 123.68% |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $1.870M | $3.336M |
| Total Long-Term Liabilities | $179.0K | $170.0K |
| Total Liabilities | $2.049M | $3.503M |
| YoY Change | -38.26% | -2.48% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | -$155.5M | -$154.5M |
| YoY Change | 7.44% | 9.34% |
| Common Stock | $145.1M | $141.9M |
| YoY Change | 3.22% | 2.53% |
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | -$164.0K | -$2.026M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $1.885M | $1.477M |
| YoY Change | -80.99% | -88.82% |
Cashflow Statement
| Concept | 2023 Q4 | 2023 Q3 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$1.023M | -$2.962M |
| YoY Change | -70.38% | -35.55% |
| Depreciation, Depletion And Amortization | $10.00K | $15.00K |
| YoY Change | -33.33% | 0.0% |
| Cash From Operating Activities | -$2.114M | -$1.317M |
| YoY Change | -2.17% | -79.32% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | $20.00K | $0.00 |
| YoY Change | -100.0% | |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | ||
| YoY Change | ||
| Cash From Investing Activities | -$20.00K | $0.00 |
| YoY Change | -100.0% | |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | ||
| YoY Change | ||
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | 2.577M | -2.000K |
| YoY Change | -5254.0% | -100.1% |
| NET CHANGE | ||
| Cash From Operating Activities | -2.114M | -1.317M |
| Cash From Investing Activities | -20.00K | 0.000 |
| Cash From Financing Activities | 2.577M | -2.000K |
| Net Change In Cash | 443.0K | -1.319M |
| YoY Change | -120.04% | -71.91% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | -$2.114M | -$1.317M |
| Capital Expenditures | $20.00K | $0.00 |
| Free Cash Flow | -$2.134M | -$1.317M |
| YoY Change | -1.25% | -81.78% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2023Q4 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
3387808000 | |
| CY2023Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
216000 | |
| CY2023Q3 | dei |
Amendment Flag
AmendmentFlag
|
false | |
| CY2023Q3 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q1 | |
| CY2023Q3 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001498382 | |
| CY2023Q3 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--06-30 | |
| CY2023Q3 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2024 | |
| CY2023Q3 | dei |
Document Type
DocumentType
|
10-Q | |
| CY2023Q3 | dei |
Document Quarterly Report
DocumentQuarterlyReport
|
true | |
| CY2023Q3 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2023-09-30 | |
| CY2023Q3 | dei |
Document Transition Report
DocumentTransitionReport
|
false | |
| CY2023Q3 | dei |
Entity File Number
EntityFileNumber
|
001-37823 | |
| CY2023Q3 | dei |
Entity Registrant Name
EntityRegistrantName
|
Kintara Therapeutics, Inc. | |
| CY2023Q3 | dei |
Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
|
NV | |
| CY2023Q3 | dei |
Entity Tax Identification Number
EntityTaxIdentificationNumber
|
99-0360497 | |
| CY2023Q3 | dei |
Entity Address Address Line1
EntityAddressAddressLine1
|
9920 Pacific Heights Blvd | |
| CY2023Q3 | dei |
Entity Address Address Line2
EntityAddressAddressLine2
|
Suite 150 | |
| CY2023Q3 | dei |
Entity Address City Or Town
EntityAddressCityOrTown
|
San Diego | |
| CY2023Q3 | dei |
Entity Address State Or Province
EntityAddressStateOrProvince
|
CA | |
| CY2023Q3 | dei |
Entity Address Postal Zip Code
EntityAddressPostalZipCode
|
92121 | |
| CY2023Q3 | dei |
City Area Code
CityAreaCode
|
858 | |
| CY2023Q3 | dei |
Local Phone Number
LocalPhoneNumber
|
350-4364 | |
| CY2023Q3 | dei |
Security12b Title
Security12bTitle
|
Common Stock | |
| CY2023Q3 | dei |
Trading Symbol
TradingSymbol
|
KTRA | |
| CY2023Q3 | dei |
Security Exchange Name
SecurityExchangeName
|
NASDAQ | |
| CY2023Q3 | dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | |
| CY2023Q3 | dei |
Entity Interactive Data Current
EntityInteractiveDataCurrent
|
Yes | |
| CY2023Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
1535000 | |
| CY2023Q3 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
567000 | |
| CY2023Q2 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
660000 | |
| CY2023Q2 | ktra |
Clinical Trial Deposit Current
ClinicalTrialDepositCurrent
|
1075000 | |
| CY2023Q3 | us-gaap |
Assets Current
AssetsCurrent
|
783000 | |
| CY2023Q3 | dei |
Entity Filer Category
EntityFilerCategory
|
Non-accelerated Filer | |
| CY2023Q3 | dei |
Entity Small Business
EntitySmallBusiness
|
true | |
| CY2023Q3 | dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
false | |
| CY2023Q3 | dei |
Entity Shell Company
EntityShellCompany
|
false | |
| CY2023Q2 | us-gaap |
Assets Current
AssetsCurrent
|
3270000 | |
| CY2023Q3 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
694000 | |
| CY2023Q2 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
709000 | |
| CY2023Q3 | us-gaap |
Assets
Assets
|
1477000 | |
| CY2023Q2 | us-gaap |
Assets
Assets
|
3979000 | |
| CY2023Q3 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
2998000 | |
| CY2023Q2 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
2784000 | |
| CY2023Q3 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
3336000 | |
| CY2023Q2 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
3082000 | |
| CY2023Q3 | ktra |
Milestone Payment Liability
MilestonePaymentLiability
|
167000 | |
| CY2023Q2 | ktra |
Milestone Payment Liability
MilestonePaymentLiability
|
166000 | |
| CY2023Q3 | us-gaap |
Liabilities
Liabilities
|
3503000 | |
| CY2023Q2 | us-gaap |
Liabilities
Liabilities
|
3248000 | |
| CY2023Q3 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
5000000 | |
| CY2023Q2 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
5000000 | |
| CY2023Q3 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2023Q2 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2023Q3 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
75000000 | |
| CY2023Q2 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
75000000 | |
| CY2023Q3 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2023Q2 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2023Q3 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
1746000 | |
| CY2023Q2 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
1692000 | |
| CY2023Q3 | us-gaap |
Common Stock Value
CommonStockValue
|
2000 | |
| CY2023Q2 | us-gaap |
Common Stock Value
CommonStockValue
|
2000 | |
| CY2023Q3 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
141855000 | |
| CY2023Q2 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
141438000 | |
| CY2023Q3 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-154512000 | |
| CY2023Q2 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-151375000 | |
| CY2023Q3 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
21000 | |
| CY2023Q2 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
21000 | |
| CY2023Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-2026000 | |
| CY2023Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
731000 | |
| CY2023Q3 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
1477000 | |
| CY2023Q2 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
3979000 | |
| CY2023Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
1859000 | |
| CY2022Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
3171000 | |
| CY2023Q3 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
1103000 | |
| CY2022Q3 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
1475000 | |
| CY2023Q3 | us-gaap |
Operating Expenses
OperatingExpenses
|
2962000 | |
| CY2022Q3 | us-gaap |
Operating Expenses
OperatingExpenses
|
4646000 | |
| CY2023Q3 | us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
-2000 | |
| CY2022Q3 | us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
11000 | |
| CY2023Q3 | us-gaap |
Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
|
2000 | |
| CY2022Q3 | us-gaap |
Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
|
39000 | |
| CY2022Q3 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
50000 | |
| CY2023Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-2962000 | |
| CY2022Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-4596000 | |
| CY2023Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-2962000 | |
| CY2022Q3 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
1906000 | |
| CY2022Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-4596000 | |
| CY2023Q3 | us-gaap |
Dividends Preferred Stock Cash
DividendsPreferredStockCash
|
2000 | |
| CY2022Q3 | us-gaap |
Dividends Preferred Stock Cash
DividendsPreferredStockCash
|
2000 | |
| CY2023Q3 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-3137000 | |
| CY2022Q3 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-4960000 | |
| CY2023Q3 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-1.83 | |
| CY2022Q3 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-3.39 | |
| CY2023Q3 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
1718000 | |
| CY2022Q3 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
1464000 | |
| CY2023Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
731000 | |
| CY2023Q3 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
160000 | |
| CY2023Q3 | ktra |
Adjustments To Additional Paid In Capital Restricted Stock Unit Expense
AdjustmentsToAdditionalPaidInCapitalRestrictedStockUnitExpense
|
47000 | |
| CY2023Q3 | ktra |
Series Preferred Stock Dividends
SeriesPreferredStockDividends
|
-2000 | |
| CY2023Q3 | us-gaap |
Profit Loss
ProfitLoss
|
-2962000 | |
| CY2023Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-2026000 | |
| CY2022Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
11795000 | |
| CY2022Q3 | ktra |
Issuance Of Shares And Warrants Net Of Issue Cost
IssuanceOfSharesAndWarrantsNetOfIssueCost
|
1903000 | |
| CY2022Q3 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
518000 | |
| CY2022Q3 | ktra |
Series Preferred Stock Dividends
SeriesPreferredStockDividends
|
-2000 | |
| CY2022Q3 | us-gaap |
Profit Loss
ProfitLoss
|
-4596000 | |
| CY2022Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
9618000 | |
| CY2023Q3 | us-gaap |
Profit Loss
ProfitLoss
|
-2962000 | |
| CY2022Q3 | us-gaap |
Profit Loss
ProfitLoss
|
-4596000 | |
| CY2023Q3 | us-gaap |
Depreciation
Depreciation
|
15000 | |
| CY2022Q3 | us-gaap |
Depreciation
Depreciation
|
15000 | |
| CY2023Q3 | ktra |
Gain Loss From Change In Fair Value Of Milestone Liability
GainLossFromChangeInFairValueOfMilestoneLiability
|
-1000 | |
| CY2022Q3 | ktra |
Gain Loss From Change In Fair Value Of Milestone Liability
GainLossFromChangeInFairValueOfMilestoneLiability
|
87000 | |
| CY2023Q3 | us-gaap |
Stock Option Plan Expense
StockOptionPlanExpense
|
160000 | |
| CY2022Q3 | us-gaap |
Stock Option Plan Expense
StockOptionPlanExpense
|
518000 | |
| CY2023Q3 | ktra |
Increase Decrease In Restricted Stock Units And Shares Issued For Services
IncreaseDecreaseInRestrictedStockUnitsAndSharesIssuedForServices
|
47000 | |
| CY2023Q3 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-93000 | |
| CY2022Q3 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
40000 | |
| CY2023Q3 | ktra |
Increase Decrease In Clinical Trial Deposits
IncreaseDecreaseInClinicalTrialDeposits
|
1075000 | |
| CY2022Q3 | ktra |
Increase Decrease In Clinical Trial Deposits
IncreaseDecreaseInClinicalTrialDeposits
|
-1700000 | |
| CY2023Q3 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
214000 | |
| CY2022Q3 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-331000 | |
| CY2023Q3 | us-gaap |
Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
|
40000 | |
| CY2022Q3 | us-gaap |
Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
|
-148000 | |
| CY2023Q3 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-1317000 | |
| CY2022Q3 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-6369000 | |
| CY2022Q3 | us-gaap |
Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
|
232000 | |
| CY2022Q3 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-232000 | |
| CY2022Q3 | ktra |
Proceeds From Issuance Of Shares And Warrants
ProceedsFromIssuanceOfSharesAndWarrants
|
1908000 | |
| CY2023Q3 | us-gaap |
Payments Of Dividends Preferred Stock And Preference Stock
PaymentsOfDividendsPreferredStockAndPreferenceStock
|
2000 | |
| CY2022Q3 | us-gaap |
Payments Of Dividends Preferred Stock And Preference Stock
PaymentsOfDividendsPreferredStockAndPreferenceStock
|
2000 | |
| CY2023Q3 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-2000 | |
| CY2023Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-1319000 | |
| CY2022Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-4695000 | |
| CY2023Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
1535000 | |
| CY2022Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
11780000 | |
| CY2023Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
216000 | |
| CY2022Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
7085000 | |
| CY2023Q3 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1 Nature of operations, corporate history, and going concern and management plans</span></p><p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Nature of operations</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Kintara Therapeutics, Inc. (the “Company”) is a clinical-stage drug development company with a focus on the development of novel cancer therapies for patients with unmet medical needs. The Company is developing two late-stage therapeutics - VAL-083 for glioblastoma and REM-001 for cutaneous metastatic breast cancer. In order to accelerate the Company’s development timelines, it leverages existing preclinical and clinical data from a wide range of sources. The Company may seek marketing partnerships in order to potentially offset clinical costs and to generate future royalty revenue from approved indications of its product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Corporate history</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is a Nevada corporation formed on June 24, 2009, under the name Berry Only, Inc. On January 25, 2013, the Company entered into and closed an exchange agreement (the “Exchange Agreement”), with Del Mar Pharmaceuticals (BC) Ltd. (“Del Mar (BC)”), 0959454 B.C. Ltd. (“Callco”), and 0959456 B.C. Ltd. (“Exchangeco”) and the security holders of Del Mar (BC). Upon completion of the Exchange Agreement, Del Mar (BC) became a wholly-owned subsidiary of the Company (the “Reverse Acquisition”).</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> On August 19, 2020, the Company completed its merger with Adgero Biopharmaceuticals Holdings, Inc., a Delaware corporation (“Adgero”) in which Adgero continued its existence under Delaware law and became a direct, wholly-owned subsidiary of the Company. Following the completion of the merger, the Company changed its name from DelMar Pharmaceuticals, Inc. to Kintara Therapeutics, Inc. and began trading on The Nasdaq Capital Market LLC (“Nasdaq”) under the symbol “KTRA”.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Kintara Therapeutics, Inc. is the parent company of Del Mar (BC), a British Columbia, Canada corporation and Adgero which are clinical-stage companies with a focus on the development of drugs for the treatment of cancer. The Company is also the parent company to Callco and Exchangeco which are British Columbia, Canada corporations. Callco and Exchangeco were formed to facilitate the Reverse Acquisition. In connection with the Adgero merger, the Company also became the parent company of Adgero Biopharmaceuticals, Inc. (“Adgero Bio”), formerly a wholly-owned subsidiary of Adgero.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">References to the Company refer to the Company and its wholly-owned subsidiaries.</span></p><p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Going concern and management plans</span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These condensed consolidated interim financial statements have been prepared on a going concern basis which assumes that the Company will continue its operations for the foreseeable future and contemplates the realization of assets and the settlement of liabilities in the normal course of business.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the three months ended September 30, 2023, the Company reported a loss of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2,962</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and a negative cash flow from operations of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1,317</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Company had an accumulated deficit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">154,512</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and had cash and cash equivalents of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">216</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> as of September 30, 2023. The Company is in the clinical stage and has not generated any revenues to date. The Company does not have the prospect of achieving revenues until such time that its product candidates are commercialized, or partnered, which may not ever occur. On August 2, 2</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">022, the Company entered into a stock purchase agreement under which the Company ultimately received approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1,903</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in net proceeds as of September 30, 2023, which is the current maximum available under the stock purchase agreement. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In ad</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">dition, on June 28, 2023, the Company announced that it had been awarded approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.0</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in grant funding to be received over a two year period for its REM-001 project.</span></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Subsequent to September 30, 2023, the Company raised net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">968</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> from its at-the-market (</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">“ATM”) facility and announced that it is suspending the development of VAL-083. Even with the proceeds from the grant funding, the stock purchase financing, and the ATM sales, the Company will require additional funding to maintain its clinical trials, r</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">esearch and development projects, and for general operations. These circumstances indicate substantial doubt exists about the Company’s ability to continue as a going concern within </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">one year</span></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> from the date of filing of these condensed consolidated interim financial statements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consequently, management is pursuing various financing alternatives to fund the Company’s operations so it can continue as a going concern. Management plans to continue to pursue opportunities to secure the necessary financing through the issue of new equity, debt, and/or entering into strategic partnership arrangements. However, the Company’s ability to raise additional capital could be affected by various risks and uncertainties including, but not limited to, global unrest. The Company may not be able to raise</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">sufficient additional capital and may tailor its drug candidate development programs based on the amount of funding the Company is able to raise in the future. Nevertheless, there is no assurance that these initiatives will be successful.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These condensed consolidated interim financial statements do not give effect to any adjustments to the amounts and classification of assets and liabilities that may be necessary should the Company be unable to continue as a going concern. Such adjustments could be material.</span></p> | |
| CY2023Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-2962000 | |
| CY2023Q3 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-1317000 | |
| CY2023Q3 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-154512000 | |
| CY2023Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
216000 | |
| CY2022Q3 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
1903000 | |
| CY2023Q3 | ktra |
Description Of Grant Funding Received
DescriptionOfGrantFundingReceived
|
In addition, on June 28, 2023, the Company announced that it had been awarded approximately $2.0 million in grant funding to be received over a two year period for its REM-001 project. | |
| CY2023Q2 | us-gaap |
Proceeds From Contributed Capital
ProceedsFromContributedCapital
|
2000000 | |
| CY2023Q3 | ktra |
Substantial Doubt About Companys Ability To Continues Going Concern Period
SubstantialDoubtAboutCompanysAbilityToContinuesGoingConcernPeriod
|
P1Y | |
| CY2023Q3 | ktra |
Stockholders Equity Reverse Stock Split Policy Policy Textblock
StockholdersEquityReverseStockSplitPolicyPolicyTextblock
|
<p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Reverse stock split</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On November 10, 2022, the Company filed a Certificate of Change to the Company’s Articles of Incorporation, as amended, in order to effectuate a 1:</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> reverse stock split (the "Reverse Stock Split") of its issued and outstanding common stock as well as its authorized shares of common stock. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a result of the Reverse Stock Split, every </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of issued and outstanding common stock were converted into one share of common stock with a proportionate reduction in the Company's authorized shares of common stock.</span></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Any fractional shares of common stock resulting from the Reverse Stock Split were rounded up to the nearest whole post-Reverse Stock Split share. The Reverse Stock Split did not change the par value of the Company's common stock. All outstanding securities entitling their holders to acquire shares of common stock were adjusted as a result of the Reverse Stock Split. All common share and per share data are retrospectively restated to give effect to the Reverse Stock Split for all periods presented herein.</span></p> | |
| CY2022Q4 | us-gaap |
Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
|
50 | |
| CY2023Q3 | us-gaap |
Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
|
As a result of the Reverse Stock Split, every 50 shares of issued and outstanding common stock were converted into one share of common stock with a proportionate reduction in the Company's authorized shares of common stock. | |
| CY2022Q4 | us-gaap |
Stock Issued During Period Shares Reverse Stock Splits
StockIssuedDuringPeriodSharesReverseStockSplits
|
50 | |
| CY2023Q3 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions about future events that affect the reported amounts of assets, liabilities, expenses, contingent assets, and contingent liabilities as at the end of, or during, the reporting period. Actual results could significantly differ from those estimates. Significant areas requiring management to make estimates include the valuation of equity instruments issued for services and clinical trial accruals. Further details of the nature of these assumptions and conditions may be found in the relevant notes to these condensed consolidated interim financial statements.</span></p> | |
| CY2023Q3 | ktra |
Patient Enrollment Milestones Payments
PatientEnrollmentMilestonesPayments
|
75000 | |
| CY2022Q3 | ktra |
Patient Enrollment Milestones Payments
PatientEnrollmentMilestonesPayments
|
1840000 | |
| CY2023Q3 | ktra |
Clinical Trial Deposit Payments
ClinicalTrialDepositPayments
|
4300000 | |
| CY2023 | ktra |
Clinical Trial Deposit Expense
ClinicalTrialDepositExpense
|
3225000 | |
| CY2023Q3 | ktra |
Deposits Payments
DepositsPayments
|
1075000 | |
| CY2023Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
275000 | |
| CY2023Q3 | ktra |
Clinical Trials Grant Disclosure Textblock
ClinicalTrialsGrantDisclosureTextblock
|
<p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:13pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4 Clinical trials grant</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Effective July 1, 2023, the Company was awarded a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Small Business Innovation Research grant from the National Institutes of Health ("NIH") to support the clinical development of REM-001 for the treatment of cutaneous metastatic breast cancer. The grant will be received in </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">two</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> tranches: approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1,250</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for the period July 1, 2023, to June 30, 2024, and approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">750</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for the period July 1, 2024, to June 30, 2025. As a result of receiving the grant, the REM-001, 15-patient clinical trial will be re-started. The grant is expended to the Company as a reimbursement of expenditures incurred. During the three months ended September 30, 2023, the Company received $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">13</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (2022 - </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">nil</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) for grants received against research and development expenditures in the period.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The grant is subject to various performance conditions and funding risk where the financial conditions of the NIH may change from time to time. The Company recognizes the grant only to the extent there is reasonable assurance the grant will be funded to the Company.</span></p> | |
| CY2023Q3 | us-gaap |
Proceeds From Grantors
ProceedsFromGrantors
|
2000000 | |
| CY2023Q3 | ktra |
Number Of Tranches
NumberOfTranches
|
2 | |
| CY2023Q2 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
709000 | |
| CY2023Q3 | us-gaap |
Depreciation
Depreciation
|
15000 | |
| CY2023Q3 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
694000 | |
| CY2023Q3 | us-gaap |
Payments For Software
PaymentsForSoftware
|
859000 | |
| CY2023 | us-gaap |
Payments For Software
PaymentsForSoftware
|
859000 | |
| CY2023Q3 | ktra |
Capitalized Cost Of Property And Equipment Not In Use
CapitalizedCostOfPropertyAndEquipmentNotInUse
|
679000 | |
| CY2023Q3 | us-gaap |
Depreciation
Depreciation
|
15000 | |
| CY2022Q3 | us-gaap |
Depreciation
Depreciation
|
15000 | |
| CY2023Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
|
275000 | |
| CY2023Q3 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
33.76 | |
| CY2023Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
|
87000 | |
| CY2023Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
105000 | |
| CY2023Q3 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
160000 | |
| CY2022Q3 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
518000 | |
| CY2023Q2 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
|
118000 | |
| CY2023Q2 | ktra |
Share Based Compensation Arrangement By Share Based Payment Award Stock Options Unvested Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsUnvestedWeightedAverageExercisePrice
|
24.12 | |
| CY2023Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
89000 | |
| CY2023Q3 | ktra |
Share Based Compensation Arrangement By Share Based Payment Award Stock Options Granted Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsGrantedWeightedAverageExercisePrice
|
4.66 | |
| CY2023Q3 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
|
26000 | |
| CY2023Q3 | ktra |
Share Based Compensation Arrangement By Share Based Payment Award Stock Options Vested Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsVestedWeightedAverageExercisePrice
|
19.5 | |
| CY2023Q3 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
|
11000 | |
| CY2023Q3 | ktra |
Share Based Compensation Arrangement By Share Based Payment Award Stock Options Forfeited Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsForfeitedWeightedAverageExercisePrice
|
11.1 | |
| CY2023Q3 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
|
170000 | |
| CY2023Q3 | ktra |
Share Based Compensation Arrangement By Share Based Payment Award Stock Options Unvested Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsUnvestedWeightedAverageExercisePrice
|
15.49 | |
| CY2023Q3 | ktra |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm
|
P9Y3M3D | |
| CY2022Q3 | ktra |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm
|
P9Y4M13D | |
| CY2022Q3 | ktra |
Non Cash Issue Costs
NonCashIssueCosts
|
289000 | |
| CY2022Q3 | ktra |
Issue Costs In Accounts Payable And Accrued Liabilities
IssueCostsInAccountsPayableAndAccruedLiabilities
|
48000 | |
| CY2022Q3 | ktra |
Equipment Additions Reclassified From Prepaid Expenses
EquipmentAdditionsReclassifiedFromPrepaidExpenses
|
447000 |
